HOME
PRODUCTS
COMPANY
CONTACT
FAQ
Research
Dictionary
Pharma
Sign Up
FREE
or
Login
Username:
Password:
Remember login
Login
Send password reminder...
Logiparin
LOGIPARIN & LHN-1 were ENs to HEPARIN, LOW-MOLECULAR-WEIGHT 1990-93
Also Known As:
LHN-1
Networked:
13
relevant articles (
2
outcomes,
3
trials/studies)
Relationship Network
Bio-Agent Context: Research Results
Carbohydrates: 22023
Polysaccharides: 15383
Glycosaminoglycans: 5640
Heparin: 24996
Low-Molecular-Weight Heparin: 6635
Logiparin: 13
Experts
1.
Hiebert, Linda M
: 1 article (01/2002)
2.
Hiebert, L M
: 1 article (07/2000)
3.
Ping, T
: 1 article (07/2000)
4.
Wice, S M
: 1 article (07/2000)
Related Diseases
1.
Thrombosis (Thrombus)
07/01/2000 - "
Compared to saline, oral Logiparin reduced the incidence of thrombosis at all doses with a dose-dependent effect suggested.
"
03/01/1993 - "
A multicentre, double-blind, randomised trial was conducted to compare the efficacy of a low-molecular-weight (LMW) heparin, Logiparin, with that of an unfractionated (UF) heparin in the prophylactic treatment of thrombosis in patients undergoing general surgery.
"
06/30/1986 - "
In conclusion, it was found that after intravenous administration LHN-1 prevented experimental thrombosis as effectively as conventional heparin.
"
01/01/2002 - "
Low molecular weight heparins were effective at lower doses than unfractionated heparins where a fifty percent reduction in thrombosis was observed with 0.025 mg/kg reviparin, 0.1 mg/kg logiparin, versus 7.5 mg/kg bovine unfractionated heparin.
"
07/01/2000 - "
A 50% reduction in thrombosis was observed at 0.1 mg/kg for oral Logiparin versus 7.5 mg/kg for unfractionated bovine lung heparin indicating that oral Logiparin is an effective antithrombotic agent at doses lower than unfractionated heparin.
"
2.
Thromboembolism
01/01/1988 - "
In conclusion, the investigated LMW-heparin (Logiparin) is safe and effective in preventing postoperative thromboembolism in patients undergoing total hip replacement, but the dosage can probably be optimized.
"
3.
Venous Thrombosis (Deep-Vein Thrombosis)
09/15/1989 - "
For future studies on the therapeutic effect of Logiparin in deep venous thrombosis a single dose of 150 to 200 F-XaI activity per 24 hours seems to be most suitable.
"
03/01/1992 - "
A total of 1290 patients (Pts) undergoing general surgery were enrolled in a randomized, multicentre double-blind study in order to investigate the efficacy and safety of two different doses of a low molecular weight heparin (LMWH) (Logiparin) for the prevention of deep vein thrombosis.
"
04/01/1991 - "
A total of 1290 patients were enrolled in a randomized multicentre double blind study in order to investigate the use of two doses of a new low molecular weight heparin, Logiparin, in the prevention of deep vein thrombosis (DVT) in general surgery.
"
04/01/1991 - "
Prevention of perioperative deep vein thrombosis in general surgery: a multicentre double blind study comparing two doses of Logiparin and standard heparin.
"
09/15/1989 - "
Treatment of deep venous thrombosis with low molecular weight heparin (LMWH-Novo, Logiparin) was carried out with two different doses of Logiparin, 75 XaI U/kg b.w.
"
4.
Hemorrhage
01/01/1988 - "
From this study it was concluded that the given dose of Logiparin was safe with regard to bleeding complications.
"
06/30/1986 - "
Bleeding times after administration of LHN-1 and conventional heparin were determined by tail transsection in anaesthetized rats and by template bleeding in the ear of conscious pigs.
"
5.
Body Weight (Weight, Body)
03/01/1993 - "
Although a correlation between plasma anti-Xa activity and body weight was observed, there is not sufficient evidence to recommend the adjustment of the Logiparin dose on patient's weight for prophylaxis in general surgery patients.
"
01/01/1991 - "
Group A (105 patients) received Logiparin (Novo-Nordisk, Denmark) 50 mg/kg body weight once daily, and group B (105 patients) received placebo once daily.
"
02/28/1989 - "
35 anti-Xa units per kg of body weight of LHN-1 (Novo).
"
02/01/1991 - "
Patients in the heparin group received 50 IU anti-Xa per kilo body weight of Logiparin once daily, and patients in the placebo group received one daily injection of saline.
"
Related Drugs and Biologics
1.
Heparin (Liquaemin)
2.
Low-Molecular-Weight Heparin (Heparin, Low Molecular Weight)
3.
Dextrans (Dextran)
4.
Therapeutic Uses
5.
ardeparin
6.
Dalteparin (Dalteparin Sodium)
7.
Enoxaparin (Lovenox)
8.
Fibrinolytic Agents (Antithrombotic Agents)
9.
Calcium
10.
reviparin (reviparin-sodium)
Related Therapies and Procedures
1.
Hip Replacement Arthroplasty (Total Hip Replacement)
2.
Intravenous Administration